TO: Pharmacy Providers

RE: CMAP COVID-19 Response – Bulletin 17: Temporary Changes to Claim Submission for Coagulation Factor Drugs

As an interim measure in response to the Governor's recent declaration of a public health emergency as the result of the outbreak of COVID-19 (coronavirus), the Department of Social Services (DSS) is temporarily suspending the paper claim submission process for Factor VII, VIII, IX, X, and XIII drugs.

Effective April 4, 2020, all anti-hemophilic factor drugs must be submitted electronically via Point of Sale (POS) using the National Council for Prescription Drug Programs (NCPDP) version D.0 format.

Electronic claim submission of coagulation factor drugs will be required until DSS has notified providers in writing that the state has deemed COVID-19 to no longer be a public health emergency (the "Temporary Effective Period").

Temporary Pricing Methodology for Claims Submitted Electronically:

Factor drug claims submitted electronically during the Temporary Effective period will be reimbursed using a custom rate. The rate will be calculated from the average of the billing provider's actual acquisition costs (AAC) obtained from invoices submitted during the first quarter of 2020. The custom rate will include the 8% markup previously paid to providers. No additional dispensing fee will be paid.

If AAC information is not available due to lack of previously submitted paper claims for the specific drug, a percent of Wholesale Acquisition Cost will be used to calculate the reimbursement.

Please Note: **Anti-Hemophilic Factors**, except for Hemlibra, are billed so that each **unit** is billed as an each. A prescription for Kogenate 50,000 units is billed as 50,000 EACH. A prescription for **Hemlibra** is billed so that each **milliliter** (ML) is billed as an EACH. A prescription for an 840 mg dosage of Hemlibra, when dispensing the National Drug Code (NDC) for Hemlibra 105 mg/ 0.7 ml would be billed as 5.6 ml.